These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23627666)

  • 21. Is increased antidepressant exposure a contributory factor to the obesity pandemic?
    Lee SH; Paz-Filho G; Mastronardi C; Licinio J; Wong ML
    Transl Psychiatry; 2016 Mar; 6(3):e759. PubMed ID: 26978741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.
    Varigonda AL; Jakubovski E; Taylor MJ; Freemantle N; Coughlin C; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):557-64. PubMed ID: 26088660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diminished functional properties of T regulatory cells in major depressive disorder: The influence of selective serotonin reuptake inhibitor.
    Jahangard L; Behzad M
    J Neuroimmunol; 2020 Jul; 344():577250. PubMed ID: 32344162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extent of cortisol suppression at baseline predicts improvement in HPA axis function during antidepressant treatment.
    Scherf-Clavel M; Wurst C; Nitschke F; Stonawski S; Burschka C; Friess L; Unterecker S; Hommers L; Deckert J; Domschke K; Menke A
    Psychoneuroendocrinology; 2020 Apr; 114():104590. PubMed ID: 32006918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothalamic-pituitary-adrenal axis activity in the comorbidity between obsessive-compulsive disorder and major depression.
    Labad J; Soria V; Salvat-Pujol N; Segalàs C; Real E; Urretavizcaya M; de Arriba-Arnau A; Ferrer A; Crespo JM; Jiménez-Murcia S; Soriano-Mas C; Alonso P; Menchón JM
    Psychoneuroendocrinology; 2018 Jul; 93():20-28. PubMed ID: 29684711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy.
    Barton DA; Esler MD; Dawood T; Lambert EA; Haikerwal D; Brenchley C; Socratous F; Hastings J; Guo L; Wiesner G; Kaye DM; Bayles R; Schlaich MP; Lambert GW
    Arch Gen Psychiatry; 2008 Jan; 65(1):38-46. PubMed ID: 18180427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidepressant treatment increased serum miR-183 and miR-212 levels in patients with major depressive disorder.
    Lin CC; Tsai MC; Lee CT; Sun MH; Huang TL
    Psychiatry Res; 2018 Dec; 270():232-237. PubMed ID: 30269040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
    Braund TA; Palmer DM; Williams LM; Harris AWF
    Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the neurobiological effects of attribution retraining group therapy with those of selective serotonin reuptake inhibitors.
    Wang C; Zhang N; Zhang YL; Zhang J; Yang H; Timothy TC
    Braz J Med Biol Res; 2013 Mar; 46(3):318-26. PubMed ID: 23558857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative stress, inflammation and treatment response in major depression.
    Lindqvist D; Dhabhar FS; James SJ; Hough CM; Jain FA; Bersani FS; Reus VI; Verhoeven JE; Epel ES; Mahan L; Rosser R; Wolkowitz OM; Mellon SH
    Psychoneuroendocrinology; 2017 Feb; 76():197-205. PubMed ID: 27960139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.
    Kennedy SE; Koeppe RA; Young EA; Zubieta JK
    Arch Gen Psychiatry; 2006 Nov; 63(11):1199-208. PubMed ID: 17088500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Atake K; Nakamura J
    Hum Psychopharmacol; 2013 Sep; 28(5):466-70. PubMed ID: 23813968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response?
    Keating C; Tilbrook A; Kulkarni J
    Int J Neuropsychopharmacol; 2011 May; 14(4):553-66. PubMed ID: 20860875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum cholesterol and serotonergic function in major depressive disorder.
    Papakostas GI; Petersen T; Mischoulon D; Hughes ME; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    Psychiatry Res; 2003 May; 118(2):137-45. PubMed ID: 12798978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cortisol stress response in post-traumatic stress disorder, panic disorder, and major depressive disorder patients.
    Wichmann S; Kirschbaum C; Böhme C; Petrowski K
    Psychoneuroendocrinology; 2017 Sep; 83():135-141. PubMed ID: 28623762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response.
    Mocking RJ; Verburg HF; Westerink AM; Assies J; Vaz FM; Koeter MW; Ruhé HG; Schene AH
    Psychoneuroendocrinology; 2015 Sep; 59():1-13. PubMed ID: 26010860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.